Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Revenue of Avidity Biosciences, Inc. (RNA)
Revenue in 2023 (TTM): $9.56 M
According to Avidity Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $9.56 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Avidity Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $9.56 M | $7.46 M | $-233,497,000 | $-212,220,000 | $-212,220,000 |
| 2022 | $9.22 M | $7.84 M | $-178,913,000 | $-173,995,000 | $-169,077,000 |
| 2021 | $9.33 M | $8.69 M | $-118,051,000 | $-118,009,000 | $-117,370,000 |
| 2020 | $6.79 M | $-30,815,000 | $-44,277,000 | $-44,355,000 | $-43,982,000 |
| 2019 | $2.32 M | $-12,220,000 | $-16,984,000 | $-24,734,000 | $-32,121,000 |
| 2018 | $379 K | $-8,057,000 | $-10,115,000 | $-11,216,000 | $-11,934,000 |